The 21st Century Cures Act, HIPAA, Big Data, and Medical Research
By Nicholson Price The 21st Century Cures Act is a big deal; the House passed it handily, and we’re still waiting to see what the Senate does. A lot has been written about what it…
Author
By Nicholson Price The 21st Century Cures Act is a big deal; the House passed it handily, and we’re still waiting to see what the Senate does. A lot has been written about what it…
By Nicholson Price [Ed. Note: On Friday, May 2 and Saturday, May 3, 2014, the Petrie-Flom Center hosted its 2014 annual conference: “Behavioral Economics, Law, and Health Policy.” This is an installment in our series of live blog posts from…
By Nicholson Price Finishing up the event today is Tom Kowalski from Vedder Price, giving a US perspective on section 101 on patentable subject matter. This post will encompass his presentation and general questions afterward.…
By Nicholson Price Third up is Dr. Maaike van der Kooij, discussing medical use claims at the EPO. In general, methods of medical treatment aren’t patentable under Art. 53(c) of the EPC, but the way…
By Nicholson Price Next up is Dr. Anja Schmitt, comparing Myriad and Mayo to EPO practice, and describing gene patents and diagnostic method patents in the EPO. Human gene patents The basic question of human gene…
By Nicholson Price I’ll be liveblogging today’s panel on Hot Topics in European Bio-Patent Law (co-sponsored by the Broad Institute), with several guest speakers from the European Patent Office (EPO). Ben Roin, Heiken Assistant Professor of…
By Nicholson Price Dov Fox had a terrific post about taxes on compensation for those who donate eggs and sperm a few weeks ago in reaction to Perez v. Commissioner. I don’t have any particularly…
By W. Nicholson Price [Ed. Note: On Friday, the Petrie-Flom Center, the Food Law and Policy Clinic (a division of the Center for Health Law and Policy Innovation), the Food Law Lab, and the Harvard Food Law Society (with support from…
By Nicholson Price There’s recently been a lot of focus on patent trolls (so called by those who dislike them; they’re also known as patent assertion entities, nonpracticing entities, and monetizers, each with slightly different…
By Nicholson Price The New York Times had a troubling piece this weekend about major problems in drug quality in India, where FDA Commissioner Margaret Hamburg is visiting to discuss safety issues. India makes 40%…